HilleVax, Inc. (NASDAQ:HLVX) Receives $3.00 Consensus Price Target from Brokerages

Shares of HilleVax, Inc. (NASDAQ:HLVX) have received an average recommendation of “Hold” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation. The average 1-year target price among brokers that have issued a report on the stock in the last year is $3.00.

Separately, HC Wainwright restated a “neutral” rating and issued a $2.00 target price on shares of HilleVax in a report on Monday.

Institutional Trading of HilleVax

Several institutional investors have recently made changes to their positions in the company. Takeda Pharmaceutical Co. Ltd. bought a new position in shares of HilleVax during the fourth quarter valued at about $13,919,000. Lightspeed Management Company L.L.C. purchased a new position in shares of HilleVax in the 4th quarter worth approximately $4,847,000. JPMorgan Chase & Co. grew its holdings in shares of HilleVax by 1,376.8% in the fourth quarter. JPMorgan Chase & Co. now owns 207,151 shares of the company’s stock valued at $429,000 after acquiring an additional 193,124 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of HilleVax during the third quarter valued at approximately $331,000. Finally, Millennium Management LLC lifted its holdings in HilleVax by 59.6% during the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company’s stock worth $852,000 after acquiring an additional 153,815 shares during the period. Institutional investors own 86.42% of the company’s stock.

HilleVax Stock Performance

Shares of HilleVax stock opened at $1.50 on Monday. HilleVax has a 52 week low of $1.37 and a 52 week high of $16.31. The stock has a 50 day moving average price of $1.79 and a two-hundred day moving average price of $1.86. The stock has a market capitalization of $74.71 million, a PE ratio of -0.48 and a beta of 0.76.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). Research analysts forecast that HilleVax will post -2.64 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.